证券代码：600080 股票简称：金花股份 编号：临 2023-041 金花企业（集团）股份有限公司 关于公司违规担保风险解除的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 金花企业（集团）股份有限公司（以下简称"公司"）原实际控制人、董事 长吴一坚违反上市公司有关对外担保规定，违规以公司名义为公司原控股股东金 花投资控股集团有限公司与西安曙光汽车销售服务有限公司于 2018 年 10 月 16 日签订的《借款合同》提供连带责任保证，该担保事项时任公司管理层、董事会、 股东大会对该事项均不知情，并未履行相应决策程序批准公司为金花投资的上述 债务提供担保。因金花投资控股集团有限公司现已被陕西省高级人民法院裁定进 行破产重整，未履行全部还款义务，西安曙光汽车销售服务有限公司向西安市仲 裁委员会提起仲裁申请，要求公司向其承担担保责任 21,895,017.36 元。具体 情况详见公司于 2023 年 2 月 11 日披露了《关于原实际控制人以公司名义违规担 保的公告》（公告编号：临 2023-009 号）。 针对上述违 ...

证券代码：600080 股票简称：金花股份 编号：临 2023-040 二、股份过户完成及协议转让前后持股情况 金花企业（集团）股份有限公司 关于持股 5%以上股东协议转让公司股份完成过户登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 金花企业（集团）股份有限公司（以下简称"公司"）于 2023 年 8 月 11 日收到持股 5%以上股东世纪金花股份有限公司（以下简称"世纪金花"）发来 的《中国证券登记结算有限责任公司过户登记确认书》，世纪金花持有的公司无 限售流通股份 18,689,910 股（占公司总股本的 5.01%）通过协议转让给南京金 伯珠资产管理有限公司-金伯珠和聚四号私募证券投资基金（以下简称"金伯珠"） 的过户登记手续已办理完毕，具体情况如下： 一、本次股份协议转让的基本情况 公司于 2022 年 9 月 1 日、2022 年 11 月 15 日、2023 年 7 月 8 日披露了《关 于持股 5%以上股东拟协议转让公司股份暨权益变动的提示性公告》、《关于持 股 5%以上股东拟协议转让公司股份 ...

2023 年 8 月 8 日，公司收到世纪金花的通知函，获悉世纪金花质押的公司 无限售流通股 12,980,000 股（占公司总股本的 3.48%）于 2023 年 8 月 7 日解除 质押，并办理完毕解除质押手续，具体事项如下： 股东名称 世纪金花股份有限公司 本次解质股份 12,980,000 占其所持股份比例 64.14% 占公司总股本比例 3.48% 解质时间 2023 年 8 月 7 日 持股数量 20,238,146 持股比例 5.42% 剩余被质押股份数量 0 剩余被质押数量占其所持股份比例 0 剩余被质押数量占公司总股本比例 0 一、股东股份解除质押情况 证券代码：600080 股票简称：金花股份 编号：临 2023-039 金花企业（集团）股份有限公司 关于持股 5%以上股东部分股权解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 金花企业（集团）股份有限公司（以下简称"公司"）持股 5%以上股 东世纪金花股份有限公司（以下简称"世纪金花"）持有公司无限售流通股 20,23 ...

金花企业（集团）股份有限公司 关于参加"2023 年陕西辖区上市公司投资者集体接待日 证券代码：600080 股票简称：金花股份 编号：临 2023-027 暨 2022 年度业绩说明会"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、业绩说明会类型 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，陕西上市公司协会根据陕 西证监局工作部署，联合深圳市全景网络有限公司举办"2023 年陕西辖区上市 公司投资者集体接待日暨 2022 年度业绩说明会活动"。 届时，金花企业（集团）股份有限公司（以下简称"公司"）总经理及相关 高管人员将通过互动平台与投资者进行网络沟通和交流，欢迎广大投资者踊跃参 加！ 二、业绩说明会召开的时间及地点 （一）召开时间：2023 年 5 月 16 日（星期二）15:00 至 17:00 （二）召开方式：网络平台在线交流 （三）网络直播地址："全景路演"（网址：http://rs.p5w.net） 三、参 ...

Financial Performance - In 2022, the company achieved a net profit of CNY 34,373,694.03, with a year-end distributable profit of CNY 515,381,407.37[5]. - The company's operating revenue for 2022 was CNY 579,374,501.21, representing an increase of 8.49% compared to CNY 534,036,500.95 in 2021[22]. - The net profit attributable to shareholders was CNY 33,459,505.16, a significant recovery from a loss of CNY 18,160,452.12 in 2021[22]. - The basic earnings per share for 2022 was CNY 0.0896, compared to a loss of CNY 0.0487 per share in 2021[22]. - The company reported a net cash flow from operating activities of CNY 52,578,993.55, an increase of 71.86% from CNY 30,594,673.93 in 2021[22]. - The total assets at the end of 2022 were CNY 1,974,418,631.97, reflecting a growth of 5.57% from CNY 1,870,188,073.55 in 2021[22]. - The company's net assets attributable to shareholders increased by 1.66% to CNY 1,683,765,383.56 at the end of 2022[22]. - The weighted average return on equity for 2022 was 2.00%, an increase of 3.08 percentage points from -1.08% in 2021[22]. - The company faced a significant decrease of 89.38% in the basic earnings per share after deducting non-recurring gains and losses, down to CNY 0.0102 from CNY 0.0961 in 2021[22]. - Total revenue for 2022 was CNY 57,937.45 million, with quarterly revenues of CNY 11,919.98 million, CNY 13,951.95 million, CNY 16,443.10 million, and CNY 15,622.41 million respectively[24]. Operational Highlights - The company emphasized digital marketing strategies and academic promotion activities to enhance brand value and market presence[30]. - The company is committed to innovation-driven development and compliance in its operations, aligning with the national "14th Five-Year Plan" for growth[30]. - The company plans to strengthen its digital marketing network and expand its online operations to improve market outcomes[30]. - The company aims to stabilize core channels and maintain effective operations while expanding new sales channels and regional market development in the pharmaceutical marketing sector[31]. - The company has increased R&D efforts on core products and initiated clinical research for the Jintian Ge capsule renewal project, alongside obtaining a patent for a method to measure cysteine and methionine in artificial tiger bone powder[31]. - The company has established a quality management system and a safety production mechanism to enhance production quality and ensure compliance with safety standards[32]. - The company is expanding its product pipeline and has initiated new product development through collaboration with university research teams, being selected for key provincial R&D projects[31]. - The company has implemented a multi-dimensional risk control process and enhanced its internal control systems to improve governance efficiency[32]. Market and Industry Trends - The online pharmaceutical sales market in China exceeded 23 billion CNY by mid-2022, indicating significant growth potential in the sector[35]. - The pharmaceutical industry in China is transitioning from rapid growth to high-quality development, with increasing emphasis on innovation and R&D investment[34]. - The market size for anti-osteoporosis drugs in hospitals increased from 9.82 billion yuan in 2017 to 11.58 billion yuan in 2021, indicating a growing demand[91]. - The prevalence of osteoporosis among individuals aged 65 and older reached 32.0% as of the end of 2021, highlighting a significant public health concern[91]. - The company’s main product, Jintian Ge capsule, has become a leading medication in orthopedic clinical applications, showcasing its competitive advantage in quality and safety[41]. Research and Development - The company is focusing on two main R&D areas: secondary development of existing core products and the development of new health food products[103]. - The company plans to enhance its core competitiveness by strengthening its R&D team and collaborating with external research institutions[103]. - The company is conducting clinical research to extend the protection period for Jintian Ge, targeting osteoporosis as the primary indication[104]. - The company’s R&D investment for the reporting period was CNY 21.65 million, accounting for 3.74% of operating revenue, which is comparable to the industry average[107]. - The company plans to increase R&D investment focusing on the pharmaceutical and health industry to drive high-quality business development[107]. Governance and Compliance - The company has established a comprehensive corporate governance structure in accordance with relevant laws and regulations, ensuring clear responsibilities among its governing bodies[137]. - The board of directors operates efficiently, with committees in place to oversee strategic, nomination, audit, and compensation matters[138]. - The company maintains independence from its controlling shareholder, ensuring no interference in its normal operations[138]. - A dedicated board secretary is responsible for information disclosure, adhering to regulatory requirements and internal management protocols[138]. - The company implemented a significant error accountability system for information disclosure in its annual report, enhancing awareness among personnel to prevent violations[139]. Environmental and Social Responsibility - The company actively engages in social responsibility, contributing 352,800 RMB in donations, including over 100,000 oral transfer factor solutions for frontline anti-epidemic efforts[191]. - The company’s environmental monitoring program includes regular assessments by third-party agencies, ensuring compliance with pollution discharge standards[187]. - The company promotes low-carbon initiatives among employees, encouraging energy-saving practices and resource recycling[190]. - The company has established a wastewater treatment station with a processing capacity of 10 m3/h (240 m3/d), ensuring that treated wastewater meets discharge standards[184]. - The company has successfully completed environmental impact assessments for existing construction projects, receiving approval from environmental authorities[184].

2023 年第一季度报告 证券代码：600080 证券简称：金花股份 金花企业（集团）股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年同期增减变动幅度(%) | | | --- | --- | --- | --- | --- | | 营业收入 | | 108,259,512.44 | | -9.18 | | 归属于上市公司股东的净利润 | | 4,680,935.36 | | -49.56 | | 归属于上市公司股东的扣除非 | | 2,350,427.63 | | -80.24 | | 经常性损益的净利润 | | | | | | 经营活动产生的现金流量净额 | | -38,760,097.98 | | 不适用 | | 基本每股收益（元/股） | | 0.0125 | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 2022 年第三季度报告 证券代码：600080 证券简称：金花股份 金花企业（集团）股份有限公司 2022 年第三季度报告 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 164,431,041.62 | 10.54 | 423,150,374. ...

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥258.72 million, representing a 6.79% increase compared to ¥242.27 million in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥21.47 million, an increase of 27.30% from ¥16.87 million in the previous year[19]. - The basic earnings per share for the first half of 2022 was ¥0.0575, up 27.21% from ¥0.0452 in the same period last year[19]. - The net cash flow from operating activities for the first half of 2022 was approximately ¥24.25 million, a significant recovery from a negative cash flow of ¥27.73 million in the previous year[19]. - The total assets at the end of the reporting period were approximately ¥1.87 billion, showing a slight increase of 0.14% from ¥1.87 billion at the end of the previous year[19]. - The company's net assets attributable to shareholders at the end of the reporting period were approximately ¥1.68 billion, reflecting a 1.30% increase from ¥1.66 billion at the end of the previous year[19]. - The weighted average return on net assets for the first half of 2022 was 1.29%, an increase of 0.31 percentage points compared to 0.98% in the same period last year[19]. - The net profit after deducting non-recurring gains and losses was 20.09 million yuan, up 42.26% year-on-year[29]. - The company achieved operating revenue of 258.72 million yuan, an increase of 6.79% year-on-year, with the pharmaceutical industry contributing 251.04 million yuan, up 8.70% year-on-year[29]. Market Position and Industry Context - As of June 2022, the pharmaceutical manufacturing industry in China generated a total revenue of 1,400.78 billion yuan, a slight decrease of 0.6% year-on-year, with total profits dropping by 27.6% to 220.95 billion yuan[23]. - The company’s main product, Jintian Ge Capsule, is recognized as a first-class new drug and has become a leading medication in orthopedic clinical applications[26]. - The company is positioned in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of various drug types, including chemical drugs and traditional Chinese medicine[26]. - The company’s core products have been included in 35 authoritative clinical guidelines, reinforcing its leading position in the orthopedic traditional Chinese medicine sector[31]. - The company is benefiting from favorable policies supporting the development of traditional Chinese medicine, which is expected to drive rapid growth in the industry[25]. - The pharmaceutical market demand is projected to continue growing due to an aging population and increasing chronic disease prevalence[24]. - The company has been recognized in the "2021 Annual Top 100 Chinese Pharmaceutical Industry" list, further solidifying its market position[31]. Research and Development - Research and development expenses decreased by 53.53% to 3.96 million yuan due to pandemic-related impacts on certain projects[44]. - The company emphasized the development of new products and technologies, increasing R&D investment and collaboration with external research institutions[39]. - The company has not disclosed any new product or technology developments in the current reporting period[78]. Environmental and Social Responsibility - The company has not faced any significant environmental issues or administrative penalties related to environmental pollution during the reporting period[68]. - The wastewater treatment capacity is 10m³/h (240m³/d), and the treated wastewater meets the discharge standards[68]. - The concentration of nitrogen oxides from the natural gas boiler after low-nitrogen transformation is 50mg/m³, complying with the emission limit of 80mg/m³[69]. - The company has implemented a comprehensive environmental monitoring plan, ensuring all pollutants are within the discharge standards[70]. - The company has adopted various measures to reduce carbon emissions, including energy-saving practices and the use of clean energy sources[73]. - The company promotes a low-carbon lifestyle among employees, encouraging energy conservation and waste reduction initiatives[74]. Financial Management and Investments - The company acquired 100% equity of Xi'an Jishitang Pharmaceutical Co., Ltd. for CNY 289,800[49]. - The company plans to develop a new product research and exhibition center in Changning New District, with a property purchase of CNY 98,000,000[50]. - The company reported a total of 1,486,296.83 RMB in related party transactions during the reporting period, with significant transactions including 747,125.60 RMB for property leasing[81]. - The company has a judicial freeze on CNY 54,046,425.80 in assets due to a legal dispute[48]. - The company is in the process of transferring 100% equity of Jin Hua International Hotel Co., Ltd., with an assessed value of CNY 368,938,800[51]. Shareholder and Corporate Governance - The total number of ordinary shareholders as of the end of the reporting period is 20,179[87]. - The largest shareholder, Xing Boyue, holds 68,881,152 shares, representing 18.45% of the total shares[89]. - The second-largest shareholder, Xinyu Xingpeng Tongchuang Enterprise Management Partnership, holds 33,448,827 shares, representing 8.96%[89]. - The company has no plans for profit distribution or capital reserve transfer for the half-year period[63]. - The employee stock ownership plan has been extended for an additional 12 months, now set to expire on March 27, 2023, with 644,700 shares sold and 644,859 shares remaining unsold[65]. Legal and Compliance Issues - The company faced 245 lawsuits related to securities false statements, with 12 cases withdrawn and 182 cases settled by the reporting date[79]. - There were no major litigation or arbitration matters reported during the period[80]. - The company has not reported any violations or penalties involving its directors, supervisors, or senior management during the reporting period[80]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance[137]. - The company conducts impairment tests on long-term assets, including fixed assets and intangible assets, at each balance sheet date[192]. - If the recoverable amount of an asset is less than its carrying amount, an impairment loss is recognized, which cannot be reversed in future periods[193]. - The company recognizes provisions for liabilities when obligations meet specific criteria, including current obligations likely to result in economic outflows[200].

Financial Performance - In 2021, the company's operating revenue was CNY 534,036,500.95, a decrease of 20.08% compared to CNY 668,180,334.76 in 2020[22] - The net profit attributable to shareholders of the listed company for 2021 was CNY -18,160,452.12, representing a decline of 148.12% from CNY 37,738,016.78 in 2020[22] - The net cash flow from operating activities was CNY 30,594,673.93, down 34.29% from CNY 46,558,370.18 in the previous year[22] - The total assets at the end of 2021 were CNY 1,870,188,073.55, a decrease of 4.51% from CNY 1,958,574,300.85 at the end of 2020[22] - The net assets attributable to shareholders of the listed company decreased by 3.78% to CNY 1,656,217,718.69 at the end of 2021 from CNY 1,721,338,898.70 at the end of 2020[22] - The basic earnings per share for 2021 was CNY -0.0487, a decrease of 145.99% compared to CNY 0.1059 in 2020[23] - The weighted average return on net assets was -1.08% in 2021, a decrease of 3.28 percentage points from 2.20% in 2020[23] - The company reported a net profit of CNY 35,853,424.89 after deducting non-recurring gains and losses, an increase of 38.31% from CNY 25,922,513.13 in 2020[22] - The net profit attributable to the parent company for the year was -18.16 million RMB, with a significant loss of -41.18 million RMB in Q4, contrasting with profits in the first three quarters[26] - The net profit after deducting non-recurring gains and losses was 35.85 million RMB for the year, with quarterly figures of 4.91 million, 9.21 million, 11.45 million, and 10.28 million RMB[26] Revenue and Sales - The company's total revenue for the year was 534.04 million RMB, with quarterly revenues of 106.80 million, 135.46 million, 148.76 million, and 143.01 million RMB respectively[26] - The pharmaceutical manufacturing segment generated sales revenue of CNY 512.47 million, down 12.82% year-on-year, primarily due to reduced sales volume impacted by the pandemic[52] - The orthopedic product sales revenue was CNY 394.89 million, a decrease of 16.95% year-on-year, with a gross margin of 87.32%[56] - The hotel segment reported operating revenue of CNY 21.85 million, an increase of 6.97% year-on-year[52] - The online pharmacy sales scale grew by 61% year-on-year in the first half of 2021, becoming an important sales channel for pharmaceuticals[38] Research and Development - R&D efforts are concentrated on core products, including process improvements and expanding indications, while also collaborating with external research institutions to enhance competitiveness[35] - The total R&D expenditure amounted to 22,484,077.16, which is 4.21% of operating revenue, with capitalized R&D accounting for 30.37% of total R&D[66] - The company is focusing on secondary development of core products and the development of new health food products, enhancing its R&D capabilities through both internal and external collaborations[97] - Key ongoing R&D projects include clinical studies for Jin Tiange and the TF series products aimed at enhancing immunity[99] - The company has completed the clinical research for Jin Tiange aimed at osteoporosis and osteoarthritis, while other projects are in various stages of research and evaluation[99] Marketing and Strategy - The company has focused on enhancing its marketing strategy, leveraging online platforms to increase brand awareness and market share in the bone and muscle health sector[34] - The company’s marketing network covers the entire country, supported by a professional academic promotion team[49] - The company is enhancing its marketing framework through academic promotion, brand building, and market research to improve sales performance[104] - The company is actively pursuing mergers and acquisitions to extend its product line and enhance its market position[114] Corporate Governance - The governance structure is robust, ensuring compliance with regulations and protecting the interests of all shareholders[123] - The company has independent directors, including Shi Ping, who received 10.00 million yuan in pre-tax compensation[128] - The company has a diverse board with members aged between 26 and 73, ensuring a range of perspectives[128] - The company has appointed new independent directors, including Yike and Zhao Ge, to strengthen its governance structure[130] - The company is actively engaging in corporate governance reforms to improve operational efficiency and accountability[130] Environmental and Social Responsibility - The company is committed to environmental protection, continuously improving its environmental management systems and reducing emissions from production sources[173] - The company engages in various charitable activities, demonstrating its commitment to corporate social responsibility[173] - The company actively promotes low-carbon initiatives, including energy-saving measures and waste reduction strategies, contributing to national carbon neutrality goals[169] - The company has established a comprehensive environmental monitoring plan, with third-party assessments confirming that all monitored pollutants meet the required standards[168] Financial Management - The company has bank entrusted wealth management with a total amount of 11,378.59 million yuan from self-owned funds and 40,000 million yuan from raised funds[185] - The company has a total of 13,533 million yuan in unexpired balances from bank entrusted wealth management[185] - The company has consistently achieved returns above 15% on various financial products, showcasing effective asset management[187][188][189][190] - The company has a plan for future investments in financial products, indicating ongoing financial strategy development[187][188][189][190] Challenges and Risks - The company is facing industry policy risks due to regulatory changes, which may lead to increased competition and challenges in the pharmaceutical sector[118] - Rising costs of raw materials and labor, along with price control measures, pose significant pressure on the company's profit growth[118] - To address risks, the company is enhancing market price monitoring and optimizing product structure while increasing investment in R&D projects[121] Employee Training and Development - The training program aims for a coverage rate of 100% for all employees, with a course opening rate of over 90%[149] - The company emphasizes the importance of internal training, with at least 70% of training sessions conducted by management and technical personnel[148] - Each employee is required to complete a minimum of 14 hours of training per year, with specific assessment criteria based on their job level[149] - The company has established a three-tier training system within the production department, focusing on GMP standards, quality regulations, and team building[150]

Financial Performance - The company's operating revenue for Q1 2022 was ¥119,199,841.13, representing an increase of 11.61% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2022 was ¥9,280,142.36, reflecting a growth of 22.92% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,893,928.31, showing a significant increase of 142.05% compared to the previous year[5] - Total revenue for Q1 2022 reached ¥119,199,841.13, an increase of 11.3% compared to ¥106,800,468.41 in Q1 2021[20] - Operating profit for Q1 2022 was ¥10,554,347.18, a decrease of 9.3% from ¥11,634,905.16 in Q1 2021[21] - Net profit for Q1 2022 was ¥9,280,142.36, up 23.0% from ¥7,549,682.33 in Q1 2021[21] - The total comprehensive income for Q1 2022 was CNY 9,280,142.36, an increase from CNY 7,549,682.33 in Q1 2021, reflecting a growth of approximately 23%[22] - The basic earnings per share for Q1 2022 was CNY 0.0249, up from CNY 0.0236 in Q1 2021, marking an increase of about 5.5%[22] - The net profit for Q1 2022 reached CNY 15,885,298.87, a significant increase of 191.5% from CNY 5,449,467.42 in Q1 2021[31] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,865,565,960.59, a slight decrease of 0.25% from the end of the previous year[6] - Total current assets decreased to ¥713,008,346.32 from ¥852,633,045.92 at the end of 2021, representing a decline of 16.4%[15] - Total non-current assets increased to ¥1,152,557,614.27 from ¥1,017,555,027.63, marking a growth of 13.2%[15] - Total liabilities decreased to ¥200,068,099.54 from ¥213,970,354.86, a reduction of 6.5%[16] - The total assets of the company as of March 31, 2022, were CNY 1,843,755,335.46, slightly up from CNY 1,843,031,565.31 at the end of 2021[28] - The total liabilities of the company decreased to CNY 179,530,793.43 as of March 31, 2022, down from CNY 194,692,322.15 at the end of 2021, reflecting a reduction of approximately 7.8%[28] Cash Flow - The net cash flow from operating activities for Q1 2022 was ¥13,070,625.82, with no applicable percentage change reported[5] - In Q1 2022, the company reported a net cash flow from operating activities of CNY 13,070,625.82, a significant improvement from a net outflow of CNY 37,984,546.27 in Q1 2021[25] - The cash flow from operating activities generated a net cash inflow of CNY 13,920,639.84, compared to a net outflow of CNY 35,939,908.41 in Q1 2021[34] - The company achieved a net cash flow from investment activities of CNY 62,615,259.10 in Q1 2022, compared to CNY 13,544,688.18 in Q1 2021, indicating a positive trend in investment returns[25] - The company reported a total cash inflow from investment activities of CNY 670,486,080.38 in Q1 2022, a significant increase from CNY 164,456,734.60 in Q1 2021[25] - The company’s cash flow from financing activities showed a net outflow of CNY 157,679.45 in Q1 2022, an improvement from a net outflow of CNY 812,500.00 in Q1 2021[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,803[9] - The top shareholder, Xing Boyue, held 17.30% of the shares, amounting to 64,566,652 shares[9] - The company's total equity attributable to shareholders was ¥1,665,497,861.05, which increased by 0.56% compared to the end of the previous year[6] - The total equity increased to CNY 1,664,224,542.03 from CNY 1,648,339,243.16, reflecting a growth in shareholder value[29] Research and Development - Research and development expenses for Q1 2022 were ¥1,632,054.20, down from ¥4,239,012.90 in Q1 2021, indicating a reduction of 61.5%[20] - Research and development expenses decreased to CNY 1,632,054.20 from CNY 4,239,012.90, indicating a strategic shift in R&D investment[30] Investment Income - The company reported a significant increase in investment income to ¥12,095,333.71 in Q1 2022, compared to ¥6,391,089.19 in Q1 2021[21] - The company reported a significant increase in investment income, totaling CNY 12,095,333.71, up from CNY 6,391,089.19 in the same period last year[30] Cash and Cash Equivalents - The company’s cash and cash equivalents increased to ¥191,330,886.39 from ¥160,802,837.08, reflecting a growth of 19.0%[14] - The company's cash and cash equivalents at the end of Q1 2022 stood at CNY 191,330,886.39, compared to CNY 344,701,160.17 at the end of Q1 2021, indicating a decrease of approximately 44.5%[26] - The company recorded a cash and cash equivalents balance of CNY 190,334,087.60 at the end of Q1 2022, compared to CNY 338,422,820.25 at the end of Q1 2021[34] Financial Expenses - The company’s financial expenses showed a significant reduction, with interest expenses at CNY 157,679.45 compared to CNY 812,500.00 in the previous year[30]